SCHEMBL2308280

SCHEMBL2308280

C[C@@H]1CN(c2c(C=O)cc(C(=O)c3ccccn3)c(F)c2F)C[C@H](C)O1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.40
KDM4E B2RXH2 4/20 0.37
HTT P42858 1/20 0.37
GLA P06280 1/20 0.35
RAB9A P51151 1/20 0.35
HSD17B14 Q9BPX1 1/20 0.34
NPC1 O15118 1/20 0.34
GAA P10253 3/20 0.33
KMT2A Q03164 3/20 0.33
ALDH1A1 P00352 3/20 0.33
MEN1 O00255 2/20 0.33
MAPT P10636 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
RBP4 P02753 1/20 0.32
HPGD P15428 1/20 0.32
GRM4 Q14833 1/20 0.32
PIK3R1 P27986 1/20 0.32
PIK3CA P42336 1/20 0.32
MTOR P42345 1/20 0.32
ALOX5AP P20292 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2312015 0.86 KDM4E (0.39) SCN9AKDM4EHTTRAB9ANPC1
SCHEMBL2310203 0.84 ALDH1A1 (0.45) SCN9AKDM4ERAB9ANPC1GAA
SCHEMBL2310229 0.84 SCN9A (0.40) SCN9AKDM4EHTTGLARAB9A
SCHEMBL3073265 0.79 KDM4E (0.38) KDM4EHTTNPC1GAAKMT2A
SCHEMBL2305202 0.79 TSHR (0.38) KDM4EHTTNPC1KMT2AALDH1A1
SCHEMBL2305463 0.76 TSHR (0.36) KDM4EHTTNPC1ALDH1A1MAPT
SCHEMBL2304904 0.76 SCN9A (0.36) SCN9AKDM4EHTTGLARAB9A
SCHEMBL3067923 0.73 KDM4E (0.39) SCN9AKDM4EHTTRAB9AGAA
SCHEMBL2508451 0.71 SCN9A (0.40) SCN9AKDM4EHTTGAAALDH1A1
SCHEMBL3056872 0.71 KDM4E (0.39) SCN9AKDM4EHTTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350077-B1 FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS ENTASIS THERAPEUTICS LTD (GB) 2016-01-27 EP disclosed
US-20150368266-A1 CHEMICAL COMPOUNDS 542 ENTASIS THERAPEUTICS INC. 2015-12-24 US disclosed
US-9040528-B2 Chemical compounds 542 ASTRAZENECA AB (SE) 2015-05-26 US disclosed
US-20140128371-A1 CHEMICAL COMPOUNDS 542 ASTRAZENECA AB (SE) 2014-05-08 US disclosed
US-8658641-B2 Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections ASTRAZENECA AB (SE) 2014-02-25 US disclosed
US-20110245224-A1 FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2011-10-06 US disclosed
EP-2350077-A1 FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AstraZeneca AB (SE) 2011-08-03 EP disclosed
WO-2010043893-A1 FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150368266-A1 CHEMICAL COMPOUNDS 542 MRPL21, CFTR, CYP3A43 SCN9A 2808/4885KDM4E 4091/4885HTT 3817/4885
US-20110245224-A1 FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS SDHB, SDHA, RORC SCN9A 3178/4885KDM4E 4677/4885HTT 4044/4885
US-20140128371-A1 CHEMICAL COMPOUNDS 542 MRPL21, CFTR, CYP3A43 SCN9A 2808/4885KDM4E 4091/4885HTT 3817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.